Healthcare professional (HCP) perceptions towards Mallya® Connectivity Cap & App for long-acting growth hormone: results from a Slovenia Participatory Study

Primož Kotnik; Klemen Dovč; Berkopec Barbara Murn; Morrow Liam Mc; Tadej Battelino

Background: Novo Nordisk’s long-acting growth hormone (LAGH) is approved by EMA for treating growth hormone deficiency (GHD) in children 3 years and older. The LAGH connected system includes the innovative add-on Mallya connectivity cap (manufactured by BIOCORP, a Novo Nordisk Company), which connects to the pen injector, detects the dose and dose time, and sends data to mobile application via Bluetooth. This marks the first LAGH connected device in Slovenia. aim Understand Health Care Providers' (HCP) perceived value of the LAGH connected system, practice integration, and associated app feature expectations to guide further development.

Methods: Focus group involved 3 paediatric endocrinologists and 1 nurse educator from the Paediatric Clinic of University Medical Centre Ljubljana, experienced in subcutaneous GH treatment and health technology. After testing the connected system, HCPs answered research questions about user experience, patient types benefiting, local needs, and future expectations. The process included audio recording, transcription, coding, and deductive thematic analysis.

Results: Focus group opinions on the use of Mallya Connectivity Cap & App for Long-Acting Growth Hormone are presented in Table 1.


User experience	Eligible individuals	Health Care Providers' (HCP) needs	Future expectations The pairing process is guided step by step, considered ideal
All individuals receiving growth hormone should have the chance to use it	The app connects directly to the hospital's EMR and transfers data	HCP portal
Enable on-screen notifications for an improved user experience	Patients who may benefit from easier tracking of concordance and correct dosing	Access to raw data (center and patient level, since last visit and treatment start)	Users can rate injection experience as acceptable or not
Automated dosing detection is a valuable feature that may improve clinical care		Growth targets in app charts to track therapy success	HCPs recommend following reminders: dose by weight out of range; discuss your dose with your doctor; change application site
HCPs believe reminders can reinforce LAGH concordance		Engaging app activities for children	Gathering data on LAGH concordance's impact on efficacy
Gathering real-world concordance data may help HCPs make informed decisions and may enhance treatment quality		Seamless connectivity is the minimum expectation

Conclusion: The LAGH connected system may gather real-world data, may enhance treatment adoption and concordance, foster HCP-patient/parent dialogue, and promote patient involvement, potentially improving care. Participants believe individuals with GHD should have the opportunity to use it, integrating it into disease management. The results also offer app developers insights into HCPs' expectations for further development.

ESPE Abstracts

P2-158